The Food and Drug Administration (FDA) has approved Cinqair (reslizumab; Teva) injection in combination with other asthma drugs for the maintenance treatment of severe asthma in patients aged ≥18 years, with an eosinophilic phenotype. It is approved for use in patients who have had a history of severe exacerbations despite their current asthma care.

Cinqair is given as an intravenous (IV) infusion every 4 weeks. Its safety and efficacy were established in five double-blind, randomized, placebo-controlled trials in patients with severe asthma on currently available therapies. Patients were administered Cinqair or placebo every 4 weeks as add-on asthma therapy.

RELATED: Positive Results for Reslizumab in Asthma Trials

Patients with severe asthma receiving Cinqair experienced less asthma exacerbations (59% reduction) and a longer time to first attack compared with placebo. Also, those receiving Cinqair had significant improvement in lung function, as measured by the volume of air exhaled by patients in one second.

Cinqair, a humanized interleukin-5 antagonist monoclonal antibody, is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. It works by reducing the levels of blood eosinophils.

The treatment is expected to become available in the second quarter of 2016. Once available, Teva will provide support, training, and education to healthcare practitioners and patients who have been prescribed Cinqair.

For more information call (888) 838-2872 or visit